EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect

Raphaëlle Corremans iD, Benjamin A Vervaet iD, Geert Dams, Patrick C D'Haese iD, Anja Verhulst iD

International Journal of Molecular Sciences · 20.05.2023 · 24 (10) · 9043

DOI: 10.3390/ijms24109043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.05.2023. Verfasst von Raphaëlle Corremans und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Metformin, Diabetes Mellitus, Experimental, Hyperglycemia. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Antwerp, Industrial Research Fund, PhD fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic Kidney Disease (DKD) is a major microvascular complication for diabetic patients and is the most common cause of chronic kidney disease (CKD) and end-stage renal disease. Antidiabetic drugs, such as metformin and canagliflozin, have been shown to exert renoprotective effects. Additionally, quercetin recently showed promising results for the treatment of DKD. However, the molecular pathways through which these drugs exert their renoprotective effects remain partly unknown. The current study compares the renoprotective potential of metformin, canagliflozin, metformin + canagliflozin, and quercetin in a preclinical rat model of DKD. By combining streptozotocin (STZ) and nicotinamide (NAD) with daily oral N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) administration, DKD was induced in male Wistar Rats. After two weeks, rats were assigned to five treatment groups, receiving vehicle, metformin, canagliflozin, metformin + canagliflozin, or quercetin for a period of 12 weeks by daily oral gavage. Non-diabetic vehicle-treated control rats were also included in this study. All rats in which diabetes was induced developed hyperglycemia, hyperfiltration, proteinuria, hypertension, renal tubular injury and interstitial fibrosis, confirming DKD. Metformin and canagliflozin, alone or together, exerted similar renoprotective actions and similar reductions in tubular injury and collagen accumulation. Renoprotective actions of canagliflozin correlated with reduced hyperglycemia, while metformin was able to exert these effects even in the absence of proper glycemic control. Gene expression revealed that the renoprotective pathways may be traced back to the NF-κB pathway. No protective effect was seen with quercetin. In this experimental model of DKD, metformin and canagliflozin were able to protect the kidney against DKD progression, albeit in a non-synergistic way. These renoprotective effects may be attributable to the inhibition of the NF-κB pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesMetforminDiabetes Mellitus, ExperimentalHyperglycemiaMaleRatsAnimalsCanagliflozinNF-kappa BQuercetinRats, WistarKidney

Stichwörter der Autor:innen

SGLT2-inhibitorchronic kidney diseasediabetic kidney diseasemetformin

Substanzen

CanagliflozinMetforminNF-kappa BQuercetin

Autor:innen und Institutionen

  • Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.

ORCID-Profile: Raphaëlle Corremans, Benjamin A Vervaet, Patrick C D'Haese, Anja Verhulst

Förderung

  • University of Antwerp
  • Industrial Research Fund
  • PhD fellowship

Zitieren

APA

Corremans, R., Vervaet, B. A., Dams, G., D'Haese, P. C., & Verhulst, A. (2023). Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect. International Journal of Molecular Sciences, 24(10), 9043. https://doi.org/10.3390/ijms24109043

Vancouver

Corremans R, Vervaet BA, Dams G, D'Haese PC, Verhulst A. Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect. International Journal of Molecular Sciences. 2023;24(10):9043. doi:10.3390/ijms24109043

BibTeX
@article{Corremans2023,
  author = {Corremans, Raphaëlle and Vervaet, Benjamin A and Dams, Geert and D'Haese, Patrick C and Verhulst, Anja},
  title = {Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {10},
  pages = {9043},
  doi = {10.3390/ijms24109043}
}
Kostenlos starten →